Loading stock data…
CAMP4 THERAPEUTICS CORPORATION (CAMP)
$4.44+0.24 (+5.71%)
After Hours$4.44+0.00 (+0.00%)· Last close Jun 29
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CAMP in the Healthcare sector is trading at $4.44 with a market capitalization of $207M. Wall Street consensus targets $8.58 (6 analysts), implying a +93.3% move over the next 12 months. The stock is currently 43% below its 52-week high of $7.75, remaining 2.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +93.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.29M↑ | $348,000↓ | $795,000↓ | $1.50M↑ | $858,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.07M↓ | -$12.78M↑ | -$13.16M↓ | -$13.03M↑ | -$13.10M |
| Net Income | -$18.33M↑ | -$40.28M↓ | -$15.10M↓ | -$12.59M↓ | -$12.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the trea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$206.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-279.27%
Volume
Today's trading volume
151,136
Recent News
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Camp4 Therapeutics...
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H
CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs) and provided an update on its lead central nervous system (CNS) program targeting SYNGAP1-related disorder during a presentation at the 25th Annual Needham Healthcare Confer
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.